BRPI0823197A2 - Anticorpos contra hepatite c e aplicações dos mesmos - Google Patents

Anticorpos contra hepatite c e aplicações dos mesmos

Info

Publication number
BRPI0823197A2
BRPI0823197A2 BRPI0823197-4A BRPI0823197A BRPI0823197A2 BR PI0823197 A2 BRPI0823197 A2 BR PI0823197A2 BR PI0823197 A BRPI0823197 A BR PI0823197A BR PI0823197 A2 BRPI0823197 A2 BR PI0823197A2
Authority
BR
Brazil
Prior art keywords
hepatitis
antibodies
applications
Prior art date
Application number
BRPI0823197-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Steven Foung
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BRPI0823197A2 publication Critical patent/BRPI0823197A2/pt

Links

Classifications

    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0823197-4A 2008-10-05 2008-10-05 Anticorpos contra hepatite c e aplicações dos mesmos BRPI0823197A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0823197A2 true BRPI0823197A2 (pt) 2015-06-23

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0823197-4A BRPI0823197A2 (pt) 2008-10-05 2008-10-05 Anticorpos contra hepatite c e aplicações dos mesmos

Country Status (12)

Country Link
US (1) US8858947B2 (enExample)
EP (1) EP2331573A4 (enExample)
JP (1) JP2012504602A (enExample)
KR (1) KR20110061624A (enExample)
CN (1) CN102197050A (enExample)
AU (1) AU2008362482A1 (enExample)
BR (1) BRPI0823197A2 (enExample)
CA (1) CA2738644A1 (enExample)
EA (1) EA201170353A1 (enExample)
IL (1) IL212040A0 (enExample)
MX (1) MX2011003613A (enExample)
WO (1) WO2010039154A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495256A4 (en) * 2009-10-30 2013-09-25 Toray Industries ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US9512183B2 (en) 2011-05-02 2016-12-06 The Johns Hopkins University Synthetic hepatitis C genome and methods of making and use
ES2859574T3 (es) 2012-08-07 2021-10-04 Massachusetts Inst Technology Anticuerpos de antivirus del dengue y usos de los mismos
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN109641955B (zh) * 2016-03-22 2022-07-08 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
CN107011435B (zh) 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026418A1 (en) * 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2004230485B2 (en) 2003-04-10 2009-01-22 Novartis Vaccines And Diagnostics, Inc. The severe acute respiratory syndrome coronavirus

Also Published As

Publication number Publication date
IL212040A0 (en) 2011-06-30
JP2012504602A (ja) 2012-02-23
US20120039846A1 (en) 2012-02-16
KR20110061624A (ko) 2011-06-09
AU2008362482A1 (en) 2010-04-08
MX2011003613A (es) 2011-08-03
CN102197050A (zh) 2011-09-21
EP2331573A1 (en) 2011-06-15
EA201170353A1 (ru) 2011-12-30
EP2331573A4 (en) 2012-09-05
US8858947B2 (en) 2014-10-14
WO2010039154A1 (en) 2010-04-08
CA2738644A1 (en) 2010-05-08

Similar Documents

Publication Publication Date Title
BRPI0823197A2 (pt) Anticorpos contra hepatite c e aplicações dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
ATE555109T1 (de) Hepatitis-c-virus-hemmer
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0907733A2 (pt) Inibidores do vírus da hepatite c
BRPI1007336A2 (pt) compostos beta-amino éster e aplicações dos mesmos.
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
CY2015004I2 (el) Αναστολεις του ιου της ηπατιτιδας c
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
CY2015012I2 (el) Αναστολεις του ιου της ηπατιτιδας c
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
EP2344481A4 (en) VIRUS AND FUNGI
BRPI1010506A2 (pt) "inibidores do vírus da hepatite c"
BRPI0822229A2 (pt) Coacervados de complexos adesivo e métodos de fabricação e uso dos mesmos
BRPI1008846A2 (pt) inibidores do vírus da hepatite c
BRPI1013393A2 (pt) inibidores do vírus da hepatite c
BRPI1014084A2 (pt) inibidores do vírus da hepatite c
BRPI0914734A2 (pt) assinaturas e determinantes associados com metástase e métodos de uso dos mesmos
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
EP3064512C0 (en) ANTIBODIES AGAINST CLDN6
BRPI0821252A2 (pt) Anticorpos ao vírus da hepatite c
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.